{"id":7722,"date":"2026-05-19T10:05:00","date_gmt":"2026-05-19T08:05:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=611be8a1bdd32c722d1651ea8daaabef"},"modified":"2026-05-19T10:05:00","modified_gmt":"2026-05-19T08:05:00","slug":"genentech-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=7722","title":{"rendered":"Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant&rsquo;s Potential to Transform the Treatment Paradigm in Early Breast Cancer"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages<\/i><\/li>\n<li>\n<i>Primary results from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease<\/i><\/li>\n<li>\n<i>Overall, nine approved and investigational medicines, including bispecific antibodies, antibody-drug conjugates and brain-permeable molecules, with ASCO data targeting urgent needs in breast, blood, lung and other cancers<\/i><\/li>\n<\/ul><p>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260518713085\/en\/2738585\/5\/GNE_Logo_Strapline_BLK_081525.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260518713085\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260518713085\/en\/2738585\/5\/GNE_Logo_Strapline_BLK_081525.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260518713085\/en\/2738585\/21\/GNE_Logo_Strapline_BLK_081525.jpg\" \/><\/a><p>\n\"Genentech\u2019s ASCO data reflect our commitment to addressing those cancers that impose the highest burden on patients and society,\" said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. \"In particular, our ASCO data highlight significant advances in breast cancer, including the latest results for giredestrant and our evolving approach to HER2-positive metastatic disease.\"<\/p><p>\n<b>Redefining the standard of care in breast cancer<\/b><\/p><p>\nGenentech's ASCO 2026 focus is on giredestrant, an investigational, oral, selective estrogen receptor degrader (SERD) being studied in early and advanced estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.<\/p><p>\nThis subtype accounts for approximately 70% of breast cancer cases, and the majority are diagnosed in the early stage. Data from three Phase III trials demonstrate giredestrant's potential as a future standard of care endocrine therapy across multiple disease stages:<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>lidERA Breast Cancer<\/b>: Building on the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15093%2F2025-12-10%2Fgenentechs-giredestrant-reduced-risk-of-&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=transformational+results&amp;index=1&amp;md5=814b4f4dd2b14e1505e3db5da77b93df\" rel=\"nofollow\" shape=\"rect\">transformational results<\/a> shared in December 2025, which demonstrated a 30% reduction in the risk of invasive disease recurrence or death, new data will indicate whether the efficacy and safety of giredestrant remain consistent across pre- and post-menopausal patients with early breast cancer. The lidERA data have been submitted to the U.S. Food and Drug Administration (FDA).<\/li>\n<li>\n<b>persevERA Breast Cancer<\/b>: Primary results investigating giredestrant in combination with palbociclib as a first-line therapy in locally advanced or metastatic cancer will be presented. These data will provide context following the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15106%2F2026-03-08%2Fgenentech-provides-update-on-phase-iii-p&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=announcement&amp;index=2&amp;md5=5e0701bd69bc091f0c700a818176583d\" rel=\"nofollow\" shape=\"rect\">announcement<\/a> that while the study did not meet its primary endpoint, the giredestrant combination showed a numerical improvement in this distinct patient population, suggesting that giredestrant is active in the first-line setting.<\/li>\n<li>\n<b>evERA Breast Cancer<\/b>: New post-progression treatment analyses will be shared exploring the sustained clinical benefit for people treated with giredestrant plus everolimus in the post-cyclin-dependent kinase 4\/6 inhibitor setting. The U.S. FDA recently <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15100%2F2026-02-19%2Ffda-accepts-new-drug-application-for-gen&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=accepted&amp;index=3&amp;md5=096c201f50d29b07fe8a236ddc0709a6\" rel=\"nofollow\" shape=\"rect\">accepted<\/a> the New Drug Application for giredestrant based on the positive evERA data.<\/li>\n<\/ul><p>\nOur ASCO data also highlight progress in HER2-positive breast cancer, an area Genentech has led for over 30 years:<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>RG6596\/ZN-A-1041 in HER2-positive breast cancer<\/b>: Preliminary results from a Phase Ic expansion <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05593094&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=trial&amp;index=4&amp;md5=d8b964d80a1bd17fc70218f485b62878\" rel=\"nofollow\" shape=\"rect\">trial<\/a> will provide early information on the safety and efficacy of ZN-A-1041, a highly blood-brain barrier-permeable, HER2-selective tyrosine kinase inhibitor, in combination with other HER2-targeted therapies, for patients with pre-treated HER2-positive metastatic breast cancer. Designed for enhanced brain penetration, ZN-A-1041 may improve the ability to prevent and treat brain metastases, a major challenge in metastatic breast cancers.<\/li>\n<\/ul><p>\n<b>Advancing precision medicine and novel combinations<\/b><\/p><p>\nGenentech is also presenting data from its diverse pipeline targeting specific genetic drivers and difficult-to-treat cancers, including:<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Divarasib in non-small cell lung cancer (NSCLC):<\/b> Genentech will present results from the Krascendo 170 Phase Ib\/II <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05789082&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=study&amp;index=5&amp;md5=5ccc3bcfaa7912c067f7a0a3d15564a0\" rel=\"nofollow\" shape=\"rect\">study<\/a> evaluating the next-generation oral KRAS G12C inhibitor divarasib combined with pembrolizumab in treatment-naive patients with KRAS G12C+ advanced NSCLC. These data informed the Phase III Krascendo 2 study, which investigates this combination as a first-line therapy regardless of PD-L1 status. Divarasib is currently being evaluated in three pivotal Phase III studies as a monotherapy or in chemotherapy-free combinations.<\/li>\n<li>\n<b>Lunsumio<sup>\u00ae<\/sup> (mosunetuzumab) plus Polivy<sup>\u00ae<\/sup> (polatuzumab vedotin) in diffuse large B-cell lymphoma (DLBCL)<\/b>: Genentech will present updated data from the Phase III SUNMO <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05171647&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=trial&amp;index=6&amp;md5=351cc9e588c7c71d431cde8f92335f95\" rel=\"nofollow\" shape=\"rect\">trial<\/a> to further establish the efficacy and safety of Lunsumio plus Polivy compared to chemotherapy (R-GemOx) particularly in second-line patients with relapsed\/refractory DLBCL who are not eligible for transplant. This first combination of a bispecific antibody and antibody-drug conjugate could potentially provide patients who often face poor prognoses and significant treatment burdens with an effective, fixed-duration, chemotherapy-free regimen.<\/li>\n<\/ul><p>\n<b>Overview of key presentations featuring Genentech medicines and molecules:<\/b><\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Medicine or\n<br\/>molecule<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Abstract title<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Abstract number\/\n<br\/>presentation details<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Breast cancer<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGiredestrant<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGiredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2\u2013 LA\/mBC): Primary analysis of the Phase III persevERA Breast Cancer (BC) trial<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#LBA1006 oral\n<br\/>\n<br\/>Breast Cancer \u2014 Metastatic<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nTuesday June 2, 2026<\/p><p class=\"bwcellpmargin\">\n11:45 - 11:57 AM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGiredestrant<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nEfficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2\u2013 eBC) in the Phase III lidERA BC clinical trial: Results by menopausal status<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#502 oral<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nBreast Cancer \u2014Local\/Regional\/Adjuvant<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSaturday May 30, 2026<\/p><p class=\"bwcellpmargin\">\n1:39 - 1:51 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGiredestrant<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPost-progression treatment (tx) analyses of evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#1016 rapid oral<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nBreast Cancer \u2014 Metastatic<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSunday May 31, 2026<\/p><p class=\"bwcellpmargin\">\n12:00 - 12:06 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nRG6596\/ ZN-A-1041<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nSafety and efficacy of ZN-A-1041, a highly blood\u2013brain barrier (BBB)-permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#1055 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nBreast Cancer \u2014 Metastatic<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nMonday June 1, 2026<\/p><p class=\"bwcellpmargin\">\n1:30 - 4:30 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nItovebi<sup>\u00ae<\/sup> (inavolisib)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOutcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 Phase III trial with <i>PIK3CA<\/i>-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2\u2013), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)\/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#1079 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nBreast Cancer \u2014 Metastatic<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nMonday June 1, 2026<\/p><p class=\"bwcellpmargin\">\n1:30 - 4:30 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nKadcyla<sup>\u00ae<\/sup> (trastuzumab emtansine)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nAdjuvant antibody\u2013drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#535 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nBreast Cancer \u2014Local\/Regional\/Adjuvant<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nMonday June 1, 2026<\/p><p class=\"bwcellpmargin\">\n1:30 - 4:30 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Blood cancer<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nLunsumio<sup>\u00ae<\/sup> (mosunetuzumab) and Polivy<sup>\u00ae<\/sup> (polatuzumab vedotin)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nMosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL): Updated efficacy and safety from the Phase III SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#7007 oral<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nHematologic Malignancies \u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSaturday May 30, 2026<\/p><p class=\"bwcellpmargin\">\n5:12 - 5:24 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nColumvi<sup>\u00ae<\/sup> (glofitamab)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nFixed-duration glofitamab monotherapy in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) with\/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: updated data after a 3.5-year follow-up<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#7006 oral<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nHematologic Malignancies \u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSaturday May 30, 2026<\/p><p class=\"bwcellpmargin\">\n5:00 - 5:12 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPolivy<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOutcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#7017 rapid oral<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nHematologic Malignancies \u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nFriday May 29, 2026<\/p><p class=\"bwcellpmargin\">\n2:12 - 2:18 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nColumvi, Lunsumio and Polivy<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nMultivariable analyses (MVAs) of overall survival (OS) in the Phase III SUNMO, STARGLO and POLARGO trials in relapsed\/refractory large B-cell lymphoma (LBCL)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#7093 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nHematologic Malignancies \u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nMonday June 1, 2026<\/p><p class=\"bwcellpmargin\">\n9:00 - 12:00 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Lung cancer<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nDivarasib<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nFirst-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic <i>KRAS<\/i> G12C+ non-small cell lung cancer (NSCLC): results from the Krascendo-170 study<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#8510 clinical science symposium<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nLung Cancer \u2014 Non-Small Cell Metastatic<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSaturday May 30, 2026<\/p><p class=\"bwcellpmargin\">\n8:36 - 8:48 AM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTecentriq<sup>\u00ae<\/sup> (atezolizumab)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTranscriptomic analyses of molecular subsets and correlations with clinical outcomes from the Phase III IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#8014 rapid oral\n<br\/>\n<br\/><\/p><p class=\"bwcellpmargin\">\nLung Cancer \u2014 Non-Small Cell Local-Regional\/Small Cell\/Other Thoracic Cancers<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSunday May 31, 2026<\/p><p class=\"bwcellpmargin\">\n5:12 - 5:18 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTecentriq<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nIMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#8086 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nLung Cancer \u2014 Non-Small Cell Local-Regional\/Small Cell\/Other Thoracic Cancers<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSunday May 31, 2026<\/p><p class=\"bwcellpmargin\">\n9:00 - 12:00 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Gastrointestinal cancer<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTecentriq<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nIMbrave251: Final analysis of atezolizumab (atezo) plus lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA\/mHCC) previously treated with atezo and bevacizumab (bev)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#4002 oral<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nGastrointestinal Cancer \u2014Gastroesophageal, Pancreatic, and Hepatobiliary<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nMonday June 1, 2026<\/p><p class=\"bwcellpmargin\">\n10:09 - 10:21 AM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTecentriq<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHealth-related quality of life (HRQOL) in the Phase III trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC)*<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#3626 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nGastrointestinal Cancer \u2014Colorectal and Anal<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSaturday May 30, 2026<\/p><p class=\"bwcellpmargin\">\n9:00 - 12:00 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Bladder cancer<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth11\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTecentriq<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth63\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPatient-reported outcomes from IMvigor011: A Phase III study of circulating tumor (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth26\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n#4627 poster<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nGenitourinary Cancer \u2014 Kidney and Bladder<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><p class=\"bwcellpmargin\">\nSunday May 31, 2026<\/p><p class=\"bwcellpmargin\">\n9:00 - 12:00 PM CDT<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n*Study led by the Alliance for Clinical Trials in Oncology and supported by Genentech<\/p><\/td><\/tr>\n<\/table><p>\n<b>Lunsumio and Lunsumio VELO U.S. Indication<\/b><\/p><p>\nLunsumio (mosunetuzumab-axgb) or Lunsumio VELO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments.<\/p><p>\nIt is not known if Lunsumio or Lunsumio VELO is safe and effective in children. The conditional approval for this use is based on response rate. There are ongoing studies to establish how well the drug works.<\/p><p>\n<b>Important Safety Information<\/b><\/p><p>\n<b>What is the most important information I should know about Lunsumio or Lunsumio VELO?<\/b><\/p><p>\n<b>Lunsumio or Lunsumio VELO can cause Cytokine Release Syndrome (CRS), <\/b>a serious side effect that is common during treatment with Lunsumio or Lunsumio VELO, and can also be severe or life-threatening.<\/p><p>\n<b>Get medical help right away if you develop any signs or symptoms of CRS at any time, including:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nfever of 100.4\u00b0F (38\u00b0C) or higher<\/li>\n<li>\nchills<\/li>\n<li>\nlow blood pressure<\/li>\n<li>\nfast or irregular heartbeat<\/li>\n<li>\ntiredness or weakness<\/li>\n<li>\ndifficulty breathing<\/li>\n<li>\nheadache<\/li>\n<li>\nconfusion<\/li>\n<li>\nfeeling anxious<\/li>\n<li>\ndizziness or light-headedness<\/li>\n<li>\nnausea<\/li>\n<li>\nvomiting<\/li>\n<\/ul><p>\n<b>Due to the risk of CRS, you will receive Lunsumio or Lunsumio VELO on a \u201cstep-up dosing schedule.\u201d<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nThe step-up dosing schedule is when you receive smaller \u201cstep-up\u201d doses before receiving higher doses of Lunsumio or Lunsumio VELO during your first cycle of treatment<\/li>\n<li>\nIf your dose of Lunsumio or Lunsumio VELO is delayed for any reason, you may need to repeat the \u201cstep-up dosing schedule\u201d<\/li>\n<li>\nYou may receive medicines to help reduce your risk of CRS before your dose<\/li>\n<\/ul><p>\nYour healthcare provider will check you for CRS during treatment with Lunsumio or Lunsumio VELO and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio or Lunsumio VELO, if you have severe side effects.<\/p><p>\n<b>What are the possible side effects of Lunsumio or Lunsumio VELO?<\/b><\/p><p>\n<b>Lunsumio or Lunsumio VELO can cause serious side effects, including:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Neurologic problems. Lunsumio or Lunsumio VELO can cause serious and life-threatening neurologic problems. <\/b>Your healthcare provider will check you for neurologic problems during treatment with Lunsumio or Lunsumio VELO. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems during or after treatment with Lunsumio or Lunsumio VELO, including:\n<ul class=\"bwlistcircle\">\n<li>\nheadache<\/li>\n<li>\nnumbness and tingling of the arms, legs, hands, or feet<\/li>\n<li>\ndizziness<\/li>\n<li>\nconfusion and disorientation<\/li>\n<li>\ndifficulty paying attention or understanding things<\/li>\n<li>\nforgetting things or forgetting who or where you are<\/li>\n<li>\ntrouble speaking, reading or writing<\/li>\n<li>\nsleepiness or trouble sleeping<\/li>\n<li>\ntremors<\/li>\n<li>\nloss of consciousness<\/li>\n<li>\nseizures<\/li>\n<li>\nmuscle problems or muscle weakness<\/li>\n<li>\nloss of balance or trouble walking<\/li>\n<li>\ntiredness<\/li>\n<\/ul><\/li>\n<li>\n<b>Serious infections.<\/b> Lunsumio or Lunsumio VELO can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with Lunsumio or Lunsumio VELO, including:\n<ul class=\"bwlistcircle\">\n<li>\nfever of 100.4\u00b0F (38\u00b0C) or higher<\/li>\n<li>\ncough<\/li>\n<li>\nchest pain<\/li>\n<li>\ntiredness<\/li>\n<li>\nshortness of breath<\/li>\n<li>\npainful rash<\/li>\n<li>\nsore throat<\/li>\n<li>\npain during urination<\/li>\n<li>\nfeeling weak or generally unwell<\/li>\n<\/ul><\/li>\n<li>\n<b>Hemophagocytic lymphohistiocytosis (HLH). <\/b>Lunsumio or Lunsumio VELO can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with Lunsumio or Lunsumio VELO. Your healthcare provider will check you for HLH especially if your CRS lasts longer than expected. Signs and symptoms of HLH include:\n<ul class=\"bwlistcircle\">\n<li>\nfever<\/li>\n<li>\nenlarged spleen<\/li>\n<li>\neasy bruising<\/li>\n<li>\nlow blood cell counts<\/li>\n<li>\nliver problems<\/li>\n<\/ul><\/li>\n<li>\n<b>Low blood cell counts. <\/b>Low<b> <\/b>blood cell counts are common during treatment with Lunsumio or Lunsumio VELO and can also be serious or severe. Your healthcare provider will check your blood cell counts during treatment with Lunsumio or Lunsumio VELO. Lunsumio or Lunsumio VELO can cause the following low blood cell counts:\n<ul class=\"bwlistcircle\">\n<li>\n<b>low white blood cell counts (lymphopenia [for Lunsumio VELO only] and neutropenia). <\/b>Low white blood cells can increase your risk for infection<\/li>\n<li>\n<b>low red blood cell counts (anemia). <\/b>Low red blood cells can cause tiredness and shortness of breath<\/li>\n<li>\n<b>low platelet counts (thrombocytopenia).<\/b> Low platelet counts can cause bruising or bleeding problems<\/li>\n<\/ul><\/li>\n<li>\n<b>Growth in your tumor or worsening of tumor-related problems (tumor flare). <\/b>Lunsumio or Lunsumio VELO can cause serious or severe worsening of your tumor.<b> <\/b>Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment with Lunsumio or Lunsumio VELO:\n<ul class=\"bwlistcircle\">\n<li>\nchest pain<\/li>\n<li>\ncough<\/li>\n<li>\ntrouble breathing<\/li>\n<li>\ntender or swollen lymph nodes<\/li>\n<li>\npain or swelling at the site of the tumor<\/li>\n<\/ul><\/li>\n<\/ul><p>\n<b>Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio or Lunsumio VELO if you develop severe side effects.<\/b><\/p><p>\n<b>The most common side effects of Lunsumio include: <\/b>CRS, tiredness, rash, headache, fever, muscle pain, cough, itching, and numbness, tingling, or pain in the hands or feet (nerve damage).<\/p><p>\n<b>The most common side effects of Lunsumio VELO include:<\/b> injection site reactions, tiredness, rash, CRS, COVID-19, muscle and joint pain, and diarrhea.<\/p><p>\n<b>The most common severe abnormal blood test results with Lunsumio include: <\/b>decreased phosphate, increased glucose, and increased uric acid levels.<\/p><p>\n<b>The most common severe abnormal blood test results with Lunsumio VELO include:<\/b> decreased white blood cell counts and increased uric acid levels.<\/p><p>\n<b>Before receiving Lunsumio<\/b> <b>or Lunsumio VELO, tell your healthcare provider about all of your medical conditions, including if you:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nhave ever had an infusion reaction after receiving Lunsumio<\/li>\n<li>\nhave an infection or have had an infection in the past which lasted a long time or keeps coming back<\/li>\n<li>\nhave or have had Epstein-Barr Virus<\/li>\n<li>\nare pregnant or plan to become pregnant. Lunsumio or Lunsumio VELO may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lunsumio or Lunsumio VELO<\/li>\n<\/ul><p>\n<b>Females who are able to become pregnant:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nyour healthcare provider should do a pregnancy test before you start treatment with Lunsumio or Lunsumio VELO<\/li>\n<li>\nuse an effective method of birth control (contraception) during your treatment and for 3 months after the last dose of Lunsumio or Lunsumio VELO<\/li>\n<li>\nare breastfeeding or plan to breastfeed. It is not known if Lunsumio or Lunsumio VELO passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of Lunsumio or Lunsumio VELO<\/li>\n<\/ul><p>\n<b>Tell your healthcare provider about all the medicines you take, <\/b>including prescription and over-the-counter medicines, vitamins, and herbal supplements.<\/p><p>\n<b>What should I avoid while receiving Lunsumio or Lunsumio VELO?<\/b><\/p><p>\n<b>Do not<\/b> drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.<\/p><p>\nThese are not all of the possible side effects of Lunsumio or Lunsumio VELO. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio or Lunsumio VELO.<\/p><p>\n<b>You may report side effects to the FDA at (800) FDA-1088 or <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;index=7&amp;md5=ad45a59e046587392b33be49688f9925\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program<\/b><\/a><b>. You may also report side effects to Genentech at (888) 835-2555.<\/b><\/p><p>\n<b>Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Flunsumio_prescribing.pdf&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=8&amp;md5=6bbbf5d4b53cfa496e10acccdfc6d236\" rel=\"nofollow\" shape=\"rect\"><b>Prescribing Information<\/b><\/a><b> and <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Flunsumio_medguide.pdf&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=Medication+Guide&amp;index=9&amp;md5=bec9b60cce1c94868a071ac1a9039336\" rel=\"nofollow\" shape=\"rect\"><b>Medication Guide<\/b><\/a><b> and Lunsumio VELO full <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Flunsumio_velo_prescribing.pdf&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=10&amp;md5=d94a03519b2e33dfcc14e7cdb019b66f\" rel=\"nofollow\" shape=\"rect\"><b>Prescribing Information<\/b><\/a><b> and <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Flunsumio_velo_medguide.pdf&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=Medication+Guide&amp;index=11&amp;md5=33c6c9cb0cfcc8c19395818608d071a4\" rel=\"nofollow\" shape=\"rect\"><b>Medication Guide<\/b><\/a><b> and on <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lunsumio.com%2F&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.Lunsumio.com&amp;index=12&amp;md5=8dee56107e9a3ffee678edd5bb396e05\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.Lunsumio.com<\/b><\/a><b>.<\/b><\/p><p>\n<b>Polivy U.S. Indication<\/b><\/p><p>\nPolivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL).<\/p><p>\nPolivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies.<\/p><p>\n<b>Important Safety Information<\/b><\/p><p>\n<b>Possible serious side effects<\/b><\/p><p>\nEveryone reacts differently to Polivy therapy, so it\u2019s important to know what the side effects are.<b> Some people who have been treated with Polivy have experienced serious to fatal side effects. <\/b>Your doctor may stop or adjust your treatment if any serious side effects occur.<b> Be sure to contact your healthcare team if there are any signs of these side effects.<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Nerve problems in your arms and legs: <\/b>This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern<\/li>\n<li>\n<b>Infusion-related reactions: <\/b>You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion<\/li>\n<li>\n<b>Low blood cell counts: <\/b>Treatment with Polivy can cause severe low blood cell counts. Your doctor will monitor your blood counts throughout treatment with Polivy<\/li>\n<li>\n<b>Infections: <\/b>If you have a fever of 100.4\u00b0F (38\u00b0C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you Polivy, which may prevent some infections<\/li>\n<li>\n<b>Rare and serious brain infections: <\/b>Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes<\/li>\n<li>\n<b>Tumor lysis syndrome: <\/b>Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy<\/li>\n<li>\n<b>Potential harm to liver: <\/b>Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication<\/li>\n<\/ul><p>\n<b>Side effects seen most often<\/b><\/p><p>\nThe most common side effects during treatment were<\/p><ul class=\"bwlistdisc\">\n<li>\nNerve problems in arms and legs<\/li>\n<li>\nNausea<\/li>\n<li>\nTiredness or lack of energy<\/li>\n<li>\nDiarrhea<\/li>\n<li>\nConstipation<\/li>\n<li>\nHair loss<\/li>\n<li>\nRedness and sores of the lining of the mouth, lips, throat, and digestive tract<\/li>\n<\/ul><p>\nPolivy may lower your red or white blood cell counts and increase uric acid levels.<\/p><p>\n<b>Polivy may not be for everyone. Talk to your doctor if you are<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Pregnant or think you are pregnant: <\/b>Data have shown that Polivy may harm your unborn baby<\/li>\n<li>\n<b>Planning to become pregnant: <\/b>Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for 5 months after their last Polivy treatment<\/li>\n<li>\n<b>Breastfeeding: <\/b>Women should not breastfeed while taking Polivy and for 2 months after the last dose<\/li>\n<\/ul><p>\nThese may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment.<\/p><p>\n<b>You may report side effects to the FDA at (800) FDA-1088 or <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;index=13&amp;md5=ac5aa72e2242f397a807994b9946ff23\" rel=\"nofollow\" shape=\"rect\"><b>http:\/\/www.fda.gov\/medwatch<\/b><\/a><b>. You may also report side effects to Genentech at (888) 835-2555.<\/b><\/p><p>\n<b>Please see the <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Fpolivy_prescribing.pdf&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=full+Prescribing+Information&amp;index=14&amp;md5=49866bdd70f577b47492b36285e9b854\" rel=\"nofollow\" shape=\"rect\"><b>full Prescribing Information<\/b><\/a><b> and visit <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.polivy.com%2F&amp;esheet=54537623&amp;newsitemid=20260518713085&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.Polivy.com&amp;index=15&amp;md5=12d23a124d6b04fc3ec6add328035f20\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.Polivy.com<\/b><\/a><b> for additional Important Safety Information.<\/b><\/p><p>\n<b>What is Itovebi?<\/b><\/p><p>\nItovebi<sup>\u00ae<\/sup> (inavolisib) is a prescription medicine used in combination with the medicines palbociclib and fulvestrant to treat adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene, and has spread to nearby tissue or lymph nodes (locally advanced), or to other parts of the body (metastatic), and has come back after hormone (endocrine) therapy.<\/p><p>\nYour healthcare provider wil<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nMedia Contact: Jared Preston (650) 467-6800\n<br\/>Advocacy Contact: Mychalleah Werner (650) 296-6218\n<br\/>Investor Contacts: Loren Kalm (650) 225-3217\n<br\/>Bruno Eschli +41 61 687 5284<\/p><br\/> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20260518713085\/en\/Genentech-to-Present-New-Data-at-ASCO-2026-Reinforcing-Giredestrants-Potential-to-Transform-the-Treatment-Paradigm-in-Early-Breast-Cancer\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP39212bri8lIe-zl5tWvCOnRHW3evRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxY5fjCLYi_If30KxIsYuhwbuLAuCkn8FS6sh-I3dfDZEg==\"> Read full story here <\/a>","protected":false},"excerpt":{"rendered":"<p>New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages<\/p>\n<p>Primary results from the persevERA study on the numerical improvement in progression-free surv&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7722","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7722"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7722\/revisions"}],"predecessor-version":[{"id":7723,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7722\/revisions\/7723"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}